Unmet Needs and Perspectives in Oral Cancer Prevention

Jebrane Bouaoud*, Paolo Bossi, Moshe Elkabets, Sandra Schmitz, Léon C. van Kempen, Pierre Martinez, Sankar Jagadeeshan, Ingrid Breuskin, Gerwin J. Puppels, Caroline Hoffmann, Keith D. Hunter, Christian Simon, Jean Pascal Machiels, Vincent Grégoire, Chloé Bertolus, Ruud H. Brakenhoff, Senada Koljenović, Pierre Saintigny*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

17 Citations (Scopus)
21 Downloads (Pure)


Oral potentially malignant disorders (OPMD) may precede oral squamous cell carcinoma (OSCC). Reported rates of malignant transformation of OPMD range from 3 to 50%. While some clinical, histological, and molecular factors have been associated with a high-risk OPMD, they are, to date, insufficiently accurate for treatment decision-making. Moreover, this range highlights differences in the clinical definition of OPMD, variation in follow-up periods, and molecular and biological heterogeneity of OPMD. Finally, while treatment of OPMD may improve outcome, standard therapy has been shown to be ineffective to prevent OSCC development in patients with OPMD. In this perspective paper, several experts discuss the main challenges in oral cancer prevention, in particular the need to (i) to define an OPMD classification system by integrating new pathological and molecular characteristics, aiming (ii) to better identify OPMD at high risk of malignant transformation, and (iii) to develop treatment strategies to eradicate OPMD or prevent malignant transformation.

Original languageEnglish
Article number1815
Issue number7
Publication statusPublished - 2 Apr 2022

Bibliographical note

Funding Information:
This research was funded by the following grant: ITMO Cancer 2020, “Formation à la Recherche Fondamentale et Translationnelle en Cancérologie” (JB); CLARA 2020 “Soutien à la mobilité des jeunes chercheurs en oncologie, [N° CVPPRCAN000198]” (JB); Fondation de France 2020 “Aide à la mobilité international de médecins et pharmaciens, [N° 00112162]” (JB); Ligue contre le Cancer 2020 (PS); INCa SIRIC-LYriCAN INCa-DGOS-Inserm_12563” (PS); Région Auvergne-Rhône-Alpes “AAP Amorçage Europe 2021” [n°21 018082 01 6 22472] (PS); “INCa [n°2021-160-AAP PREV-BIO21-008]–Projet ISEBIO” (PS); “AIRC IG [nr 21740]” (PB).

Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.


Dive into the research topics of 'Unmet Needs and Perspectives in Oral Cancer Prevention'. Together they form a unique fingerprint.

Cite this